Author： Howell Paul M. Liu Zixing Khong Hung T.
Publisher： MDPI
E-ISSN： 1424-8247|3|7|2022-2044
ISSN： 1424-8247
Source： Pharmaceuticals, Vol.3, Iss.7, 2010-07, pp. : 2022-2044
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy.
Related content
Access to resources
Recommend
Use of Inotropic Agents in Treatment of Systolic Heart Failure
By Tariq Sohaib Aronow Wilbert S.
International Journal of Molecular Sciences, Vol. 16, Iss. 12, 2015-12 ,pp. :
Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer
By Alcorn Sara Walker Amanda J. Gandhi Nishant Narang Amol Wild Aaron T. Hales Russell K. Herman Joseph M. Song Danny Y. DeWeese Theodore L. Antonarakis Emmanuel S. Tran Phuoc T.
International Journal of Molecular Sciences, Vol. 14, Iss. 7, 2013-07 ,pp. :